StreetInsider.com News Articles

Mira Pharmaceuticals reports oral formulation progress for MIRA-55

Fri, 10 Jul 2026 08:02:46 -0400

Mira Pharmaceuticals, Inc. (NASDAQ: MIRA) announced preclinical results from formulation studies of MIRA-55, an oral drug candidate being developed as a non-opioid therapy for chronic inflammatory pain.

The company said it evaluated multiple oral formulations and selected a lead candidate that demonstrated oral bioavailability, sustained systemic exposure, and distribution into brain and liver tissue following oral administration, according to a press release.

The study included an intravenous reference arm to measure absolute oral bioavailability and support selection of the lead formulation based on its pharmacokinetic profile. The company said brain exposure may support modulation of central pain-processing pathways, while distribution to peripheral

Mira Pharmaceuticals reports oral formulation progress for MIRA-55

Fri, 10 Jul 2026 08:02:46 -0400

Form 8-K MIRA PHARMACEUTICALS, For: Jul 10

Fri, 10 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260710/26755334.html

Form 8-K MIRA PHARMACEUTICALS, For: Jul 10

Fri, 10 Jul 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260710/26755334.html

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

Fri, 10 Jul 2026 08:00:00 -0400

Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain and Liver Distribution Following Oral Administration

MIAMI, FL / ACCESS Newswire / July 10, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company, today announced positive results from preclinical studies evaluating optimized oral formulations of MIRA-55, the Company's oral drug candidate being developed as a non-opioid therapy for chronic inflammatory pain.

Following evaluation of multiple oral formulations, the Company selected a lead formulation demonstrating favorable oral bioavailability together with sustained systemic exposure and reproducible distribution into both

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

Fri, 10 Jul 2026 08:00:00 -0400

Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain and Liver Distribution Following Oral Administration

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

Mon, 06 Jul 2026 09:00:00 -0400

New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with Once-Daily Dosing Potential

MIAMI, FL / ACCESS Newswire / July 6, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company, today announced positive results from preclinical studies evaluating the optimized oral formulation of SKNY-1, the Company's oral drug candidate being developed for obesity and addiction-related disorders.

The studies demonstrated favorable oral bioavailability together with reproducible systemic exposure and robust brain penetration, and substantial liver exposure following oral administration. Peak plasma concentrations were observed approximately

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

Mon, 06 Jul 2026 09:00:00 -0400

New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with Once-Daily Dosing Potential

Form 8-K MIRA PHARMACEUTICALS, For: Jul 06

Mon, 06 Jul 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260706/26733467.html

Form 8-K MIRA PHARMACEUTICALS, For: Jul 06

Mon, 06 Jul 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260706/26733467.html

Mira Pharmaceuticals reports new preclinical data on Mira-55

Thu, 25 Jun 2026 08:15:16 -0400

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced new preclinical pharmacology data showing that its cannabinoid analog Mira-55 displays a distinct mechanism of action compared to THC and produces anxiety-reducing effects that THC does not, according to a company press release.

The study tested THC and Mira-55 alongside rimonabant, a drug that blocks the CB1 receptor, using three standard measures used to characterize THC-like activity: body temperature, movement, and muscle rigidity, as well as anxiety-like behavior.

THC produced the full pattern associated with CB1 activity — lowered body temperature, reduced movement, and catalepsy — all of which were reversed by rimonabant. Mira-55 produced only

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

Thu, 25 Jun 2026 08:15:00 -0400

Data show Mira-55 does not produce the central nervous system effects associated with THC and acts through a distinct pharmacological mechanism, while demonstrating anxiolytic activity, which THC does not produce, supporting continued development for chronic inflammatory pain

MIAMI, FL / ACCESS Newswire / June 25, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, today announced new preclinical pharmacology data on Mira-55, the Company's cannabinoid analog in development for chronic inflammatory pain. Mira-55 is designed to act on

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

Thu, 25 Jun 2026 08:15:00 -0400

Form 8-K MIRA PHARMACEUTICALS, For: Jun 25

Thu, 25 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260625/26688543.html

Form 8-K MIRA PHARMACEUTICALS, For: Jun 25

Thu, 25 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260625/26688543.html

Form 8-K MIRA PHARMACEUTICALS, For: Jun 17

Wed, 17 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26657104.html

Form 8-K MIRA PHARMACEUTICALS, For: Jun 17

Wed, 17 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26657104.html

MIRA Pharmaceuticals files Phase 2a trial protocol for CIPN drug

Wed, 17 Jun 2026 08:00:23 -0400

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) has submitted a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration for Ketamir-2, its oral NMDA receptor modulator, targeting chemotherapy-induced peripheral neuropathy (CIPN).

The planned study, designated Protocol Mira-002, is a randomized, double-blind, placebo-controlled, three-period crossover trial to evaluate the safety, tolerability, and dose-response relationship of oral Ketamir-2 in patients with moderate-to-severe persistent CIPN. The trial will be conducted at a U.S. cancer center. Patients will receive Ketamir-2 at either 300 mg or 600 mg, or a placebo, across three sequential seven-day treatment periods separated by two-week washout intervals, with each participant

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

Wed, 17 Jun 2026 08:00:00 -0400

Randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and dose-response efficacy of oral Ketamir-2 at a leading U.S. cancer center

MIAMI, FL / ACCESS Newswire / June 17, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced the submission of a Phase 2a clinical trial protocol to the U.S. Food and Drug Administration (FDA) for Ketamir-2, the Company's proprietary oral NMDA receptor modulator, in chemotherapy-induced peripheral neuropathy (CIPN).

Addressing a Significant Unmet Medical Need

Chemotherapy-induced peripheral neuropathy is

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

Wed, 17 Jun 2026 08:00:00 -0400

Randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and dose-response efficacy of oral Ketamir-2 at a leading U.S. cancer center

Addressing a Significant Unmet Medical Need

Chemotherapy-induced peripheral neuropathy is

Form 4 MIRA PHARMACEUTICALS, For: Jun 12 Filed by: MacPherson Edward Clouston